Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong.
Hong Kong Med J. 2012 Oct;18(5):412-8.
OBJECTIVE. To evaluate the clinical outcome and safety of stereotactic ablative radiotherapy for medically inoperable stage I non-small-cell lung carcinoma. DESIGN. Retrospective case series. SETTING. Pamela Youde Nethersole Eastern Hospital, Hong Kong. PATIENTS. All patients with medically inoperable stage I non-small-cell lung carcinoma receiving stereotactic ablative radiotherapy since its establishment in 2008. MAIN OUTCOME MEASURES. Disease control rate, overall survival, and treatment toxicities. RESULTS. Sixteen stage I non-small-cell lung carcinoma patients underwent the procedure from June 2008 to November 2011. The median patient age was 82 years and the majority (81%) had moderate-to-severe co-morbidity based on the Adult Comorbidity Evaluation 27 index. With a median follow-up of 22 months, the 2-year primary tumour control rate, disease-free survival and overall survival rates were 91%, 71% and 87%, respectively. No grade 3 (National Cancer Institute Common Terminology Criteria for Adverse Events) or higher treatment-related complications were reported. CONCLUSION. Stereotactic ablative radiotherapy can achieve a high degree of local control safely in medically inoperable patients with early lung cancer.
评估立体定向消融放疗治疗无法手术的 I 期非小细胞肺癌的临床疗效和安全性。
回顾性病例系列研究。
中国香港东区尤德夫人那打素医院。
所有自 2008 年立体定向消融放疗设立以来患有无法手术的 I 期非小细胞肺癌且不适合进行其他治疗的患者。
疾病控制率、总生存率和治疗毒性。
2008 年 6 月至 2011 年 11 月期间，16 例 I 期非小细胞肺癌患者接受了该治疗。患者中位年龄为 82 岁，根据成人合并症评估 27 指数，大多数（81%）患者合并有中重度合并症。中位随访时间为 22 个月，2 年原发肿瘤控制率、无疾病生存率和总生存率分别为 91%、71%和 87%。未报告 3 级（美国国立癌症研究所常见不良事件术语标准）或更高的与治疗相关的并发症。
立体定向消融放疗可以为无法手术的早期肺癌患者提供安全的高度局部控制。
